A Phase 2 interventional study of Zanubrutinib and Supportive Care in COVID-19 Pulmonary Complications and COVID-19, sponsored by BeiGene. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.
Among the 1,859 studies in COVID-19 with a site in United States, this one is the 737th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 299th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
Shionogi · Sites in United States, Bulgaria, Japan
Ages 12+
ModernaTX, Inc. · Sites in United States, Argentina, Dominican Republic and 3 more countries
Ages 6 mo–11 yrs · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,859 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 240 · Phase 2 481 · Phase 3 244 · Phase 4 60
First in 2007; this study’s year is marked. 818 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 91 across the 1,321 interventional studies, 300 across the 521 observational. Of the 1,414 that completed or were terminated, 720 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
638 of 1,859 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 3 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
85 of the studies in COVID-19 with a site in United States that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
Add all 85 to your calendar (.ics) → With an account.
Among the 1,859 studies in COVID-19 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received zanubrutinib plus supportive care
Drug: Zanubrutinib · Drug: Supportive Care
Participants received placebo plus supportive care alone
Drug: Supportive Care · Drug: Placebo
320 mg (4 x 80 mg) capsules administered orally once daily
Also known as: BGB-3111, Brukinsa
Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Placebo to match zanubrutinib
Number of Participants With Respiratory Failure-free Survival
Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28
Time frame: Up to Day 28
Time to Breathing Room Air
Time to return to breathing room air is defined as the time from randomization date to the earliest time where the participant is stable on room air without supplemental oxygen. Total follow-up time in days is the total time of all participants from the randomization date to the first event date or Day 28 if there is no event. The rate was calculated as total number of events in which a participant returned to breathing room air on or before Day 28 divided by the total follow-up time in days.
Time frame: Up to 7 months
Number of Participants Experiencing Respiratory Failure or Death
Number of participants experiencing respiratory failure or death on or before Day 28
Time frame: Up to Day 28
Number of Participants With All-cause Mortality
Number of participants with all-cause mortality on or before Day 28
Time frame: Up to Day 28
Number of Participants Discharged Alive
Number of participants discharged alive on or before Day 28
Time frame: Up to Day 28
Number of Participants Discharged Alive From the ICU
Number of participants discharged alive from the intensive care unit (ICU) on or before Day 28
Time frame: Up to Day 28
Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale
Number of participants with improvement in WHO 8-point-scale, in which improvement was considered a score that changed from ≥4 at baseline to ≤ 3 at Day 28 as assessed by the investigator. Scoring ranges from 0 = uninfected with no clinical or virologic evidence of disease to 8 = dead.
Time frame: Up to Day 28
Duration of Mechanical Ventilation
Number of days on mechanical ventilation on or before Day 28
Time frame: Up to Day 28
Duration of Hospitalization
Number of days hospitalized on or before Day 28
Time frame: Up to Day 28
PaO2:FiO2 Ratio
Partial pressure of oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio
Time frame: Baseline, Day 7, Day 14, Day 21 and Day 28
Number of Participants With Adverse Events
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), treatment-related adverse events (AEs), and TEAEs grade 3 or higher, including laboratory findings
Time frame: Up to 7 months
A total of 63 participants were randomized to receive zanubrutinib or placebo; four were randomized to the placebo group, but did not receive placebo treatment due to death (1 participant) and investigator decision (3 participants).
| Milestone | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Started | 30 | 33 |
| Completed | 13 | 17 |
| Not completed | 17 | 16 |
| Withdrew: Death | 3 | 4 |
| Withdrew: Lost to follow-up | 11 | 8 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Withdrew: Physician decision | 0 | 3 |
Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants With Respiratory Failure-free Survival | 27 | 28 |
Time to return to breathing room air is defined as the time from randomization date to the earliest time where the participant is stable on room air without supplemental oxygen. Total follow-up time in days is the total time of all participants from the randomization date to the first event date or Day 28 if there is no event. The rate was calculated as total number of events in which a participant returned to breathing room air on or before Day 28 divided by the total follow-up time in days.
| Events / total follow-up in days | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Time to Breathing Room Air | 0.060 | 0.061 |
Number of participants experiencing respiratory failure or death on or before Day 28
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants Experiencing Respiratory Failure or Death | 3 | 5 |
Number of participants with all-cause mortality on or before Day 28
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants With All-cause Mortality | 2 | 4 |
Number of participants discharged alive on or before Day 28
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants Discharged Alive | 26 | 28 |
Number of participants discharged alive from the intensive care unit (ICU) on or before Day 28
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants Discharged Alive From the ICU | 3 | 2 |
Number of participants with improvement in WHO 8-point-scale, in which improvement was considered a score that changed from ≥4 at baseline to ≤ 3 at Day 28 as assessed by the investigator. Scoring ranges from 0 = uninfected with no clinical or virologic evidence of disease to 8 = dead.
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale | 22 | 25 |
Number of days on mechanical ventilation on or before Day 28
| Days | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Duration of Mechanical Ventilation | 4.0 (3 to 24) | 13.5 (3 to 26) |
Number of days hospitalized on or before Day 28
| Days | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Duration of Hospitalization | 6.5 (3 to 28) | 5.0 (1 to 28) |
Partial pressure of oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio
| mmHg | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| Baseline | — | 53.0 (53.0 to 53.0) |
| Day 7 | 82.00 (75.00 to 89.00) | 54.00 (52.80 to 84.30) |
| Day 14 | 32.00 (32.00 to 32.00) | 90.60 (90.60 to 90.60) |
| Day 21 | — | 52.10 (52.10 to 52.10) |
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), treatment-related adverse events (AEs), and TEAEs grade 3 or higher, including laboratory findings
| Participants | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| At least one TEAE | 19 | 20 |
| Grade 3 or higher | 6 | 6 |
| Serious adverse event | 4 | 7 |
| Treatment-related TEAE | 2 | 1 |
Collected over Up to 7 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zanubrutinib + Supportive Care | 3/30 (10%) | 4/30 (13.3%) | 19/30 (63.3%) |
| Placebo + Supportive Care | 4/33 (12.1%) | 7/29 (24.1%) | 20/29 (69%) |
| Event | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| HypoxiaRespiratory, thoracic and mediastinal disorders | 1/30 | 2/29 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/30 | 2/29 |
| AnaemiaBlood and lymphatic system disorders | 0/30 | 1/29 |
| Right ventricular failureCardiac disorders | 0/30 | 1/29 |
| Ischaemic strokeNervous system disorders | 0/30 | 1/29 |
| Acute kidney injuryRenal and urinary disorders | 1/30 | 1/29 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/30 | 1/29 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/30 | 1/29 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 0/30 | 1/29 |
| COVID-19 pneumoniaInfections and infestations | 1/30 | 0/29 |
| Event | Zanubrutinib + Supportive Care | Placebo + Supportive Care |
|---|---|---|
| BradycardiaCardiac disorders | 5/30 | 0/29 |
| HypomagnesaemiaMetabolism and nutrition disorders | 0/30 | 3/29 |
| HeadacheNervous system disorders | 1/30 | 3/29 |
| HypokalaemiaMetabolism and nutrition disorders | 3/30 | 1/29 |
| ConstipationGastrointestinal disorders | 2/30 | 2/29 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/30 | 2/29 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/30 | 2/29 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/30 | 2/29 |
| DiarrhoeaGastrointestinal disorders | 2/30 | 1/29 |
| NauseaGastrointestinal disorders | 2/30 | 0/29 |
The Intent-to-Treat (ITT) Analysis Set includes all randomized participants
| Age, Continuous(Years) | Zanubrutinib + Supportive Care | Placebo + Supportive Care | Total |
|---|---|---|---|
| Mean | 56.0 ± 12.51 | 56.0 ± 13.30 | 56.0 ± 12.83 |
| Sex: Female, Male(Participants) | Zanubrutinib + Supportive Care | Placebo + Supportive Care | Total |
|---|---|---|---|
| Female | 16 | 16 | 32 |
| Male | 14 | 17 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Zanubrutinib + Supportive Care | Placebo + Supportive Care | Total |
|---|---|---|---|
| Hispanic or Latino | 13 | 6 | 19 |
| Not Hispanic or Latino | 16 | 26 | 42 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Zanubrutinib + Supportive Care | Placebo + Supportive Care | Total |
|---|---|---|---|
| Asian | 2 | 2 | 4 |
| Black or African American | 3 | 5 | 8 |
| White | 19 | 25 | 44 |
| Other | 1 | 1 | 2 |
| Unknown | 3 | 0 | 3 |
| Not Reported | 2 | 0 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jul 2020 to primary completion in Feb 2021, 6 months.
Results were first posted in Mar 2022, 1 year 1 month after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 6 months is below that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zanubrutinib